<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000600439">
  <TermName>brivanib alaninate</TermName>
  <TermPronunciation>(brih-VAN-ib a-luh-NIH-nayt)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000720613" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;brivanib alaninate&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000720614" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;alaninato de brivanib&quot;" language="es" id="_4"/>
  <SpanishTermName>alaninato de brivanib</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Es posible que el alaninato de brivanib impida la formación de los vasos sanguíneos nuevos que los tumores necesitan para crecer y  destruya células cancerosas. Es un tipo de antiangiogénico y de inhibidor del receptor 2 del factor de crecimiento endotelial vascular.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2008-07-17</DateFirstPublished>
  <DateLastModified>2009-04-24</DateLastModified>
</GlossaryTerm>
